The vaccine segment reported 15 per cent Y-o-Y growth, driven by strong growth for Boostrix, Variritix, and Fluarix. In addition, GSK Pharma is intensifying efforts to increase adult immunisation ...
Background: The trivalent inactivated split-influenza vaccine, Fluarix TM has been available since 1992. Aim: To assess the safety and immunogenicity of the vaccine from studies in healthy adults ...
Sales of the influenza vaccine, Fluarix, rose 14%. Sales of Established vaccines improved 8%. During the quarter, GSK did not record any sales from the COVID-19 booster vaccine, which was co ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback